Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 13, Issue 5, Pages 515-524Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0071
Keywords
-
Categories
Funding
- Eisai
- Bristol-Myers Squibb
- Genentech BioOncology
- Merck
- Novartis Oncology
- Novocure
- Boehringer Ingelheim Pharmaceuticals, Inc.
Ask authors/readers for more resources
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available